+ Watch ACAD
on My Watchlist
The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.
Acadia has now completely retraced last spring's stirrapulated price spike to 3 and may be headed closer to last fall's all-time low of 0.66. 36M in cash now backs a 51M market cap and quarterly burn is hanging around 5M as the clock ticks towards topline data for study 020 of pimavanserin in Parkinson's psychosis in mid-2012. I've faceplanted on many bottom-feeding moonshot picks over the last couple of years (see Hemispheryx, Cel-Sci, Rexahn, and more than a few others), so I wouldn't bet that this is the end of the drop for Acadia. But I do think this will be a stock to watch closely as phase III data approaches. As for the results? The prior failure of pimavanserin in two phase III trials for the same indication doesn't bode well.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions